Guides Collective
The Weekly Guide
Resources, research, and reflections — curated each week for the guides in our community.
MAY 27, 2026
Section 01
Industry Headlines
What's happening in the psychedelic space this week.
JAMA NETWORK OPEN · MAY 15, 2026
Single Dose of Psilocybin Provides Rapid Relief From Depression in Double-Blind Study
A single 25 mg dose produced symptom improvement within days at Karolinska Institutet — with 53% of psilocybin participants achieving remission at six weeks, compared to just 6% on niacin placebo.
JAMA NETWORK OPEN · MAY 12, 2026
Psilocybin Shows Promise for Treating Cocaine Addiction in Landmark Randomized Trial
A placebo-controlled trial found a single psilocybin dose combined with psychotherapy significantly increased cocaine-free days — nearly 30% of participants achieved complete six-month abstinence, versus 0% on placebo.
PSYCHEDELIC ALPHA · MAY 27, 2026
Field Notes: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval
Josh Hardman's debut Field Notes episode examines the APA conference, ibogaine developments following an executive order, FDA leadership shifts, and the tightening race between Compass Pathways and Usona Institute toward psilocybin approval.
Section 02
From the Field
Perspectives and insights from leaders in the psychedelic space.
Josh Hardman · Psychedelic Alpha
"If I Can't Change My Views Based on Evidence, Then Why Do Science at All?" — Nora Volkow on Psychedelics
Josh Hardman · Psychedelic Alpha
Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making
Section 03
Personal Journeys
First-person accounts worth reading — perspectives that inform the work we do.
STAT NEWS · FEBRUARY 19, 2026
I Took Part in a 2012 Psilocybin Trial. What I'm Seeing Now Horrifies Me.
NORMALIZE PSYCHEDELICS · JANUARY 23, 2026
What Changed After 38 Years Sober: Linda's First Psychedelic Experience
Section 04
From the Platform
What's new and coming to Guides Collective.
Test 1
Test 2